Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company developing biologic therapeutics for immune homeostasis, has announced its upcoming participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 10:00 a.m. E.T. in Boston, MA. The presentation will be accessible via webcast on Q32 Bio's website, with replays available for 90 days after the event.
Q32 Bio (Nasdaq: QTTB), una compagnia biotecnologica in fase clinica che sviluppa terapie biologiche per l'omeostasi immunitaria, ha annunciato la sua prossima partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. La direzione della società parteciperà a una chiacchierata informale martedì, 12 novembre 2024, alle 10:00 E.T. a Boston, MA. La presentazione sarà accessibile tramite webcast sul sito di Q32 Bio, con le registrazioni disponibili per 90 giorni dopo l'evento.
Q32 Bio (Nasdaq: QTTB), una empresa biotecnológica en etapa clínica que desarrolla terapias biológicas para la homeostasis inmune, ha anunciado su próxima participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. La dirección de la empresa participará en una charla informal el martes 12 de noviembre de 2024, a las 10:00 a.m. E.T. en Boston, MA. La presentación estará disponible a través de un webcast en el sitio web de Q32 Bio, con repeticiones disponibles durante 90 días después del evento.
Q32 Bio (Nasdaq: QTTB)는 면역 항상성을 위한 생물학적 치료제를 개발하는 임상 단계의 생명공학 회사로, 구겐하임의 제1회 의료 혁신 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사 경영진은 2024년 11월 12일 화요일 오전 10시(동부 표준시)에 매사추세츠 주 보스턴에서 진행되는 대화에 참여할 것입니다. 발표는 Q32 Bio의 웹사이트를 통해 웹캐스트로 접속할 수 있으며, 행사 후 90일 동안 재생 가능할 것입니다.
Q32 Bio (Nasdaq: QTTB), une entreprise de biotechnologie en phase clinique développant des thérapies biologiques pour l'homéostasie immunitaire, a annoncé sa prochaine participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. La direction de l'entreprise participera à une discussion informelle le mardi 12 novembre 2024, à 10h00 E.T. à Boston, MA. La présentation sera accessible en ligne via le site web de Q32 Bio, avec des rediffusions disponibles pendant 90 jours après l'événement.
Q32 Bio (Nasdaq: QTTB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das biologische Therapeutika zur Immunhomöostase entwickelt, hat seine bevorstehende Teilnahme an der Ersten Gesundheitsinnovationskonferenz von Guggenheim bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 12. November 2024, um 10:00 Uhr E.T. in Boston, MA, an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast auf der Website von Q32 Bio zugänglich sein, mit Wiedergaben, die 90 Tage nach der Veranstaltung verfügbar sind.
- None.
- None.
A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-guggenheims-inaugural-healthcare-innovation-conference-302295851.html
SOURCE Q32 Bio
FAQ
When is Q32 Bio (QTTB) presenting at Guggenheim's Healthcare Innovation Conference 2024?
How long will Q32 Bio's (QTTB) Guggenheim Conference presentation replay be available?
Where can I watch Q32 Bio's (QTTB) Guggenheim Conference presentation?
What type of event will Q32 Bio (QTTB) participate in at the Guggenheim Conference?
